Daré Bioscience reports Q1 2026 cash $18.5M; first product revenue expected June 2026

Dare Bioscience, Inc.

2026-Q1 EPS reported -$0.21 revenue$152,455

Cash and equivalents $18.5M as of March 31; working capital ~$0.5M; revenue $0.2M from Gates Foundation services.
Ovaprene Phase 3 trial receives second positive DSMB review; enrollment expected to complete in 2026 with 2027 primary endpoint analysis.
DARE to PLAY sildenafil cream dispensing to commence summer 2026; pre-fulfillment prescribing active in all 50 states.
Flora Sync LF5 commercial launch in June 2026; first-ever product revenue milestone expected that month.
DARE-HPV Phase 2 study starting May 2026 with ARPA-H funding; DARE to RECLAIM targeting 2027 dispensing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, a copy of which is furnished as Exhibit 99.1 to this report.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001401914-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.